Crescent Biopharma, Inc.
NASDAQ: CBIO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Joshua T. Brumm
- Employees
- 41
- Headquarters
- Waltham, United States
- IPO year
- 2014
- Market cap
- $478.6M
- Website
- https://crescentbiopharma.com
Loading CBIO…
Loading profile data…Frequently asked questions about CBIO
What does Crescent Biopharma, Inc. (CBIO) do?
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-00...
Where does CBIO trade?
Crescent Biopharma, Inc. (CBIO) trades on the NASDAQ Capital Market.
What sector is CBIO in?
Crescent Biopharma, Inc. (CBIO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Crescent Biopharma, Inc.?
Joshua T. Brumm is the chief executive officer of Crescent Biopharma, Inc. (CBIO).
Where is Crescent Biopharma, Inc. headquartered?
Crescent Biopharma, Inc. is headquartered in United States.
Does CBIO pay a dividend?
Crescent Biopharma, Inc. (CBIO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CBIO go public?
Crescent Biopharma, Inc. (CBIO) completed its initial public offering in 2014.